Comparative Pharmacology
Head-to-head clinical analysis: ANKTIVA versus GLATOPA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANKTIVA versus GLATOPA.
ANKTIVA vs GLATOPA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ANKTIVA is a live attenuated, nonpathogenic recombinant strain of Vibrio cholerae O1 (CVD 103-HgR) that colonizes the intestinal mucosa and elicits protective mucosal and systemic immune responses against V. cholerae, including production of vibriocidal and antitoxin antibodies.
Glatiramer acetate (GLATOPA) is a mixture of synthetic polypeptides that alters immune processes by inducing and expanding T-helper 2 (Th2) regulatory cells, which suppress pro-inflammatory T-helper 1 (Th1) cells. It also competes with myelin basic protein for binding to major histocompatibility complex (MHC) molecules, thereby modulating antigen presentation and reducing autoimmune attack on myelin.
Intravesical instillation of 300 mg (25 mL) once weekly for 6 weeks, followed by maintenance therapy of 300 mg once monthly for 6 or 12 months.
20 mg subcutaneously once daily.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours; clinically, steady-state reached after 2-3 days
The terminal elimination half-life of glatiramer is approximately 1.5–2 hours after subcutaneous administration. This short half-life is due to rapid proteolytic degradation; however, the clinical effect persists for days due to immunological mechanisms.
Renal: ~70% unchanged; fecal: ~30% as metabolites
Glatiramer acetate is extensively metabolized locally at the injection site and systemically by proteolysis. The metabolites are eliminated primarily via renal excretion (approximately 70%) and biliary/fecal excretion (approximately 30%). Less than 1% is excreted unchanged.
Category C
Category C
Immunomodulator
Immunomodulator